Citations 2
Safety and Feasibility of Concomitant Urogynecologic and Gynecologic Oncology Surgical Procedures
Wohlrab, Kyle, Robison, Katina, Rahn, David D. , Dunivan, Gena C., Occhino, John, Pennycuff, Jon, Frimer, Marina, Lokich, Elizabeth, Ring, Kari, Uyar, Denise , Winer, Ira, Richter, Holly E., Wohlrab, Kyle J., Robison, Katina M. , Occhino, John A. , Pennycuff, Jon F., Frimer, Marina , Ring, Kari Lassen , Winer, Ira Seth , Richter, Holly E
Urogynecology | January 27, 2026 | Volume: 32 | Issue: 2 | Pages: 76-89
This joint Clinical Consensus Statement on the safety and feasibility of concomitant urogynecologic and gynecologic oncology surgical procedures reflects statements drafted by content experts from the American Urogynecologic Society and the Society of Gynecologic Oncology. The writing group used a Delphi process to evaluate statements developed from a structured literature search and assessed consensus. A total of 35 statements were assessed in the following categories: (1) background, (2) treatment options, (3) timing of concurrent surgery, (4) risk factors, and (5) value-based care. Of the 35 statements, 28 reached consensus on initial review. Three statements were omitted, and 4 statements were revised and reached consensus following second review utilizing the Delphi process.
Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279
Horowitz, Neil S. , Peterson, I., Mannel, Robert S., Thompson, J. S. , Lokich, Elizabeth, Myers, Tashanna , Hanjani, P., O’Malley, David M. , Chung, Ki Y. , Miller, David S. , Dizon, Don S. , Mayadev, Jyoti , Monk, Bradley J. , Peterson, Ivy, Thompson, Spencer , Myers, Tashanna , O'Malley, David M , Miller, David S , Ueland, Frederick R , Dizon, Don S , Miller, Austin , Mayadev, Jyoti S , Leath, Charles A , Monk, Bradley J , Deng, Wei, Miller, Austin
Journal of Clinical Oncology | April 4, 2024 | Volume: 42 | Issue: 16 | Pages: 1914-1921
PURPOSE To assess efficacy and toxicity of cisplatin (C) and gemcitabine (G) with intensity-modulated radiation therapy (IMRT) in patients with locally advanced vulvar cancer not amenable to surgery. METHODS Patients enrolled in a single-arm phase II study. Pretreatment inguinal-femoral nodal assessment was performed. Sixty-four Gy IMRT was prescribed to the vulva, with 50-64 Gy delivered to the groins/low pelvis. Radiation therapy (RT) plans were quality-reviewed pretreatment. C 40 mg/m2 and G 50 mg/m2 were administered once per week throughout IMRT. Complete pathologic response (CPR) was the primary end point. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method, and adverse events were assessed with Common Terminology Criteria for Adverse Events v 4.0. RESULTS Fifty-seven patients enrolled, of which 52 were evaluable. The median age was 58 years (range, 25-58), and 94% were White. Forty (77%) had stage II or III disease, and all had squamous histology. A median of six chemotherapy cycles (range, 1-8) were received. Eighty-five percent of RT plans were quality-reviewed with 100% compliance to protocol. Seven patients came off trial because of toxicity or patient withdrawal. Of 52 patients available for pathologic assessment, 38 (73% [90% CI, 61 to 83]) achieved CPR. No pelvic exenterations were performed. With a median follow-up of 51 months, the 12-month PFS was 74% (90% CI, 62.2 to 82.7) and the 24-month OS was 70% (90% CI, 57 to 79). The most common grade 3 or 4 adverse events were hematologic toxicity and radiation dermatitis. There was one grade 5 event unlikely related to treatment. CONCLUSION Weekly C and G concurrent with IMRT sufficiently improved CPR in women with locally advanced vulvar squamous cell carcinoma not amenable to surgical resection.